Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


November 27, 2013
Church Attendance and Late HIV Diagnosis Linked Among MSM
Men who have sex with men (MSM) who attend church are more likely to receive an HIV diagnosis late in the course of their infection.
November 26, 2013
The Gay HIV Epidemic Is Increasing in All Nations
The upward trajectory of HIV infection trends among gay men worldwide points to a dire future for that demographic.
November 25, 2013
HIV-Positive People Under 50 May Suffer More Stress, Isolation
People living with HIV who are younger than 50 suffer from greater levels of stress and isolation than the older generation.
November 24, 2013
Vaginal Ring May Prevent HIV and Pregnancy for 90 Days
Early research suggests that the future of both HIV and pregnancy prevention among women may be in an intravaginal ring that works for 90 days.
November 21, 2013
Sex in Prison Is Common Among Black Male Inmates
Black men make up a large proportion of HIV-positive men in prison, where sex between men is common and concern about HIV is limited.
November 20, 2013
Turn Holiday Gift Cards Into HIV Vaccine Research Funds
For the holidays, the gift card retailer Gyft is teaming with Immunity Project, an HIV vaccine research group, to raise research dollars.
November 18, 2013
New Statin Guidelines Hit Snag With Faulty Risk Calculator
Those taking statins to lower cholesterol need not reduce levels to any specific point, rather they just need to take the correct dose, say new guidelines.
ViiV Submits Single-Pill Combo of Tivicay and Epzicom to FDA
ViiV Healthcare has submitted an application to the FDA for approval of a single-tablet regimen to treat HIV that combines Tivicay and Epzicom.
November 15, 2013
New HIV Care Guidelines Urge Focus on Other Health Matters
The HIV Medicine Association has revised its HIV care guidelines, urging clinicians to focus outside of the virus as many patients live normal life spans.
November 14, 2013
Rates of Failure in HIV Drugs Vary Widely in Poorer Nations
There is a vast range in outcomes of success at suppressing HIV with antiretroviral treatment among people taking the drugs in poorer nations.
Incivek Improves Outcomes for HIV/HCV Coinfected Gay Men
Incivek added to interferon and ribavirin shortens the treatment duration and raises cure rates among gay, HIV-positive men with acute hepatitis C.
November 13, 2013
Baseline Viral Load, Time to Suppression Dictate Rebound Risk
Having a higher viral load when beginning HIV treatment and taking longer to fully suppress the virus each up the risk of a viral rebound.
November 12, 2013
False Reports Say Bisexuals Have Same HIV Risk as Straights
Multiple media outlets have erroneously reported that the risk of HIV for bisexual men in the U.S. is comparable to the risk for heterosexual men.
November 11, 2013
Heart Attack Risk Rises if CD4s Ever Dip Below 200
The risk of heart attack among people with HIV is linked to a depleted immune system, specifically if CD4s dip below 200.
November 08, 2013
HIV Uses ‘Invisibility Cloak’ to Evade Immune System
HIV uses a kind of “invisibility cloak” to hide in cells without alerting the body’s immune response—a finding that may lead to new treatments.
Hardened Arteries Are Linked to HIV Rather than ARVs
HIV infection rather than antiretroviral treatment is linked to a risk for atherosclerosis (hardening of the arteries) among those who have never smoked.
November 06, 2013
Long-Acting HIV Drugs Could Extend Lives of Low Adherers
Long-acting antiretrovirals could improve life expectancy among people with HIV, especially those with low adherence to daily regimens.
November 05, 2013
Treatment as Prevention Is Cost-Effective in Poorer Nations
Treating the HIV-positive member of a serodiscordant couple is cost-effective in resource-limited settings.
November 04, 2013
Sofosbuvir and Ribavirin Fare Well Among HIV-HCV Coinfected
Sofosbuvir and ribavirin cured between 67 and 88 percent of those coinfected with HIV and genotypes 1, 2 or 3 of hepatitis C virus in a recent trial.
New Sangamo Genetic Therapy Boosts CD4s, Reduces Reservoir
A study of a genetic therapy has reduced the size of the HIV reservoir in seven of nine study subjects and has also led to long-term CD4 increases.
November 01, 2013
Sustiva Raises Suicide Risk, But Absolute Risk Is Still Low
Sustiva (efavirenz) doubles the rate of suicidality among those starting therapy for the first time, although the overall risk remains minimal.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adoniz89
    san dimas
    California


    Sloan1
    Dallas
    Texas


    Heartland4now
    Tacoma
    Washington


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.